Yes, one of the best NP interviews ever IMO.
Post# of 153995
(Total Views: 371)
Posted On: 11/14/2019 4:00:38 PM
Yes, one of the best NP interviews ever IMO.
He has stated such before, but provided alittle more clarity today about potential cancer BTD. He said if we enroll 2 more patients and their initial CTC readout is similar to the first patient they will filed for BTD. This could be this year if 2 patients are enrolled and injected by early December (NP said after first readout post baseline.....so 2-3 weeks)......and the initial patient results were 'stunning' with the lowest dose of 350mg!!
I've been confidnet in cancer success for a long time now, so this is very exciting to me. I doubt NP would say 3 patients and a single readout if this hasn't been discussed with CRO, KOLs and/or FDA already. Reading a little between the lines and cancer is for real.
What is even more scary is that NP was more excited about NASH....maybe because that's the newest shiny toy on the BP playground and should bring in some big cash?
He has stated such before, but provided alittle more clarity today about potential cancer BTD. He said if we enroll 2 more patients and their initial CTC readout is similar to the first patient they will filed for BTD. This could be this year if 2 patients are enrolled and injected by early December (NP said after first readout post baseline.....so 2-3 weeks)......and the initial patient results were 'stunning' with the lowest dose of 350mg!!
I've been confidnet in cancer success for a long time now, so this is very exciting to me. I doubt NP would say 3 patients and a single readout if this hasn't been discussed with CRO, KOLs and/or FDA already. Reading a little between the lines and cancer is for real.
What is even more scary is that NP was more excited about NASH....maybe because that's the newest shiny toy on the BP playground and should bring in some big cash?
(3)
(0)CytoDyn Inc (CYDY) Stock Research Links
Please do your own due diligence. All my posts and comments are not to be considered investment advice.